All Blogs
Aug 22, 2025
Hemophilia A Beyond Standard Factor Therapies: Can Gene Therapy, anti-TFPI, and siRNA Siege HEMLIBRA and ALTUVIIIO’s Throne?
Over the past four decades, hemophilia A treatment has advanced remarkably. Beginning with the introduction of cryoprecipitate in 1964, treatment progressed to plasma-derived FVIII, then to recombinant FVIII therapies in the 1980s. The 1990s and 2000s saw the rise of Standard Half-life (SHL) products, followed by E...
Read More...
Aug 21, 2025
FDA Grants 510(k) Clearance to Nerveblox AI; Labcorp Introduces the First FDA-Cleared Alzheimer’s Blood Test; Calidar Introduces First-of-its-Kind 4D Mammography System; ONWARD Medical to Initiate Empower BP Pivotal Study Following FDA IDE Approval; Tenon® Medical Launches Catamaran® SE SI Joint Fusion System Nationwide; Rivanna Secures $800,000 Virginia Catalyst Grant Plus Matching Funds to Advance AI-Driven Ultrasound Innovation
Nerveblox, the Ultrasound AI for Regional Anesthesia Received FDA Clearance On August 18, 2025, Nerveblox, an AI-powered software developed by SmartAlpha to assist physicians in performing ultrasound-guided regional anesthesia, received U.S. Food and Drug Administration (FDA) 510(k) clearance. This milesto...
Read More...
Aug 20, 2025
Top 5 Surgical Simulation Companies Revolutionizing Surgical Education
Surgical simulation has emerged as one of the most transformative shifts in medical education and practice. With patient safety at the forefront and growing pressure to reduce medical errors, simulation technologies offer a safe, controlled, and repeatable way to train. Unlike traditional cadaver labs or observatio...
Read More...
Aug 19, 2025
Precigen’s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis; Tonix’s Tonmya Becomes First FDA-Approved Fibromyalgia Treatment in Over 15 Years; FDA Extends BLA Review for REGENXBIO’s RGX-121 in MPS II Patients; SystImmune’s Izalontamab Brengitecan (EGFRxHER3 ADC) Gets FDA Breakthrough Designation for EGFR-Mutated NSCLC; Soligenix Granted FDA Orphan Drug Status to SGX945 for Behçet’s Disease Therapy Following Phase II Success
Precigen’s PAPZIMEOS Wins Full FDA Approval for Recurrent Respiratory Papillomatosis Precigen, Inc. announced that the FDA has granted full approval to PAPZIMEOS (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). The decision makes PAPZIMEOS the first and on...
Read More...
Aug 18, 2025
Asthma Uncontrolled: Why Better Treatments Haven’t Fixed the Crisis
“We have inhalers that can save lives in seconds and biologics that can change the course of the disease—so why are millions still wheezing in emergency rooms (ERs)?” A Global Paradox in Respiratory Health Asthma today stands at the intersection of remarkable scientific progress and sobering real-world stagna...
Read More...
Aug 15, 2025
Triple Threat to Clostridioides difficile Infections: New Antibiotics, Biotherapeutics & Vaccines
Clostridioides difficile infection (CDI) remains a significant public health challenge worldwide, especially in healthcare settings. Despite advancements in diagnosis and treatment, the Clostridioides difficile infection treatment market is characterized by persistent therapeutic limitations, particularly the high ...
Read More...
Aug 14, 2025
Nyxoah Secures FDA Nod for Genio® System in OSA Treatment; FDA Grants First 510(k) Clearance to DeepSight™-Powered NeedleVue™ LC1 Ultrasound System; TITAN CSR® Retractor Tops U.S. Military List for Trauma Care in Deployed Settings; FDA Clears Myra Vision to Begin US IDE Study for Glaucoma; HistoIndex Advances Fibrosis Assessment with AI-Powered FibroSIGHT™ Plus; Gentuity Partners with GE HealthCare to Broaden Access to Cutting-Edge Intravascular Imaging
FDA Approves Nyxoah’s Genio® System for Treating Obstructive Sleep Apnea On August 08, 2025, Nyxoah SA, a medical technology company that developed breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, announced that the U.S. Food and Drug Administration (FDA) had a...
Read More...
Aug 13, 2025
Top 5 Big Data Applications in Healthcare Revolutionizing Patient Care
Over the past decade, big data in healthcare has evolved from a promising concept into a transformative force reshaping patient care, clinical research, and hospital operations. What began as fragmented data stored in electronic health records has now expanded into massive, interconnected datasets drawn from wearab...
Read More...
Aug 12, 2025
Teva’s AJOVY Expanded by FDA as First Anti-CGRP Preventive for Pediatric Episodic Migraine; NRx Pharma’s NRX-100 Granted FDA Fast Track for Suicidal Ideation in Depression/Bipolar Depression; Boehringer Ingelheim’s HERNEXEOS Wins FDA Accelerated Approval for HER2-Mutant Advanced NSCLC; Genmab’s Phase III EPCORE FL-1 Meets Dual Endpoints in Relapsed/Refractory Follicular Lymphoma; Tiziana’s Phase II IND Cleared by FDA for Multiple System Atrophy
FDA Expands Teva’s AJOVY As First Anti-CGRP Preventive For Pediatric Episodic Migraine Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the FDA has approved AJOVY (fremanezumab-vfrm) for the preventive treatment of episodic migraine in children and adolescents aged 6–...
Read More...
Aug 11, 2025
The Next Wave in Sarcopenia Drug Development: 5 Therapies to Look Out
Although there are no approved sarcopenia drugs at present, ongoing research is exploring possible pharmacological solutions. Investigational treatments include Selective Androgen Receptor Modulators (SARMs) and myostatin inhibitors, which aim to enhance muscle mass and function. Beyond non-pharmacological approach...
Read More...